Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 21, 2024 17:00 ET
|
Instil Bio
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported...
Instil Bio Announces Strategic Update
January 16, 2024 08:00 ET
|
Instil Bio
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte,...
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 05, 2023 17:00 ET
|
Instil Bio
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte,...
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 17:00 ET
|
Instil Bio
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023 07:00 ET
|
Instil Bio
DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 07:00 ET
|
Instil Bio
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational...
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26, 2023 16:38 ET
|
Instil Bio
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development,...
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:00 ET
|
Instil Bio
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H’2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11,...
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023 07:00 ET
|
Instil Bio
Instil confirms cash runway beyond 2026 ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 ...
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 31, 2023 17:00 ET
|
Instil Bio
Company anticipates cash resources to provide runway beyond 2026 Initial clinical data from the ITIL-306 program expected in 2023 Instil is consolidating manufacturing and Phase 1 clinical trial of...